RBC Capital Markets upgrades Wave Life Sciences after strong siRNA therapy results for obesity. Read more here.

RBC Life Sciences, Inc manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company's Nutritional Products ...

Fintel reports that on December 9, 2025, RBC Capital upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from Sector Perform to Outperform. Analyst Price Forecast Suggests 9.81% Upside As of ...

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

As previously reported, RBC Capital analyst Luca Issi upgraded Wave Life Sciences (WVE) to Outperform from Sector Perform with a price target of ...